MGC Pharmaceuticals Limited (MXC.L) LSE
21.20
-0.8(-3.64%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
MGC Pharmaceuticals Limited
Address
1202 Hay Street
West Perth, WA 6005
Australia
Phone
61 8 6382 3390
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
N/A
First IPO Date
February 09, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Roby Reuven Zomer | Co-Founder, Chief Executive Officer, MD & Executive Director | 183,303 | 1980 |
| Sasha Friedman | Deputy Chief Executive Officer | 0 | N/A |
| Yifat Steuer | Deputy Chief Executive Officer & Chief Operating Officer | 0 | N/A |
| Nadya Lisovoder | Chief Medical Officer | 0 | N/A |
| Tom Cairns | Chief Accounting Officer | 0 | N/A |
| Nicole Ann Godresse | Global Chief Sales Officer | 0 | N/A |
| Sabina Suljakovic | Head of the Quality Assurance Department | 0 | N/A |
| Yair Tal | Chief Information Security Officer | 0 | N/A |
| Amir Polak | Chief Pharmaceutical Development Officer | 0 | N/A |
| Robert Clements | Chief Commercial Officer | 0 | N/A |
Description
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company's principal product candidates include CimetrA, which is in phase III clinical trial for early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for symptomatic relief of Dementia. It has research and development agreement with Royal Melbourne Institute of Technology and the University of Notre Dame; and collaboration agreement with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.
